Johnson & Johnson (JNJ) Net Margin (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Net Margin came in at 21.76% in Q1 2026, down 2848.0% year-on-year from 0.79% in Q1 2025, and up 4.46% quarter-over-quarter from 20.83% in Q4 2025.
Johnson & Johnson (JNJ) Net Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Net Margin across 17 years of filings, most recently posting 21.76% for Q1 2026.
- Net Margin for Q1 2026 came in at 21.76%, down 2848.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 21.83% (up 952.0% YoY), and the FY2023 annual result was 25.63%, up 2367.0% from the prior year.
- Net Margin came in at 21.76% for Q1 2026 at Johnson & Johnson, up from 20.83% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 101.72% in Q4 2023 to a low of 1.08% in Q3 2023.
- The 4-year median for Net Margin is 2.91% (2022), against an average of 19.06%.
- Across the five-year window, Net Margin soared 10098 bps in 2023 and plunged 2848 bps in 2026, its largest moves.
- Johnson & Johnson's Net Margin stood at 0.74% in 2022, then sank by 152 bps to 0.39% in 2023, then jumped by 5469 bps to 20.83% in 2025, then grew by 4 bps to 21.76% in 2026.
- The last three Net Margin figures came in at 21.76% (Q1 2026), 20.83% (Q4 2025), and 21.47% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 22.77% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 23.32% |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 21.76% |
| Dec 28, 2025 | 20.83% |
| Sep 28, 2025 | 21.47% |
| Jun 29, 2025 | 23.32% |
| Mar 30, 2025 | 50.24% |
| Dec 31, 2023 | -0.39% |
| Oct 1, 2023 | 101.72% |
| Jul 2, 2023 | -1.08% |
| Apr 2, 2023 | 2.02% |
| Jan 1, 2023 | 1.47% |
| Oct 2, 2022 | 0.74% |
| Jul 3, 2022 | 2.73% |
| Apr 3, 2022 | 2.91% |
| Oct 3, 2021 | 15.71% |
| Jul 4, 2021 | 26.93% |
| Apr 4, 2021 | 27.76% |
| Jan 3, 2021 | 7.73% |
| Sep 27, 2020 | 16.86% |
| Jun 28, 2020 | 19.78% |
| Mar 29, 2020 | 28.01% |